Jubilant Pharmova Limited — Q1 FY26 earnings call

Call held 31 Jul 2025

Management summary

Jubilant Ingrevia delivered a strong start to FY26, characterized by record profitability in its Specialty Chemicals segment and a significant recovery in bottom-line metrics. While the Nutrition segment faced pricing headwinds in Niacinamide, the company is pivoting toward higher-value Human Nutrition and leveraging favorable regulatory shifts in Europe for Choline Chloride. Management remains focused on the execution of its 'Pinnacle 345' strategy, backed by a ₹600 crore capex plan for the fiscal year.

Highlights

  • Overall revenue stood at ₹1,038 crore, a marginal 1.4% YoY increase, with volume growth of 5% despite macro challenges.

  • EBITDA grew significantly by 29% YoY to ₹153 crore, driven by margin expansion in Specialty Chemicals.

  • PAT increased by 54% YoY to ₹75 crore, up from ₹49 crore in Q1 FY25.

  • Specialty Chemicals segment achieved its highest-ever EBITDA of ₹130 crore with a robust 27% margin.

  • The $300 million big Agro CDMO contract remains on track for supply commencement in early 2026.

  • Lean 2.0 cost-optimization program targets annualized savings exceeding ₹100 crore in FY26.

  • EU imposed a 125% anti-dumping duty on Chinese Choline Chloride, creating a major export opportunity for the company.

Key financials

  1. Revenue ₹1,038 Cr +1.4%YoY
  2. EBITDA ₹153 Cr +29%YoY
  3. EBITDA Margin 14.7%
  4. PAT ₹75 Cr +54%YoY
  5. Net Debt ₹700 Cr

What they filed

Q1 FY27: revenue up 12.8%, net profit up 25.9% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue61 56 61 60 66 +8%67 +20%70 +16%67 +13%
EBITDA10 10 11 10 12 +18%12 +22%15 +33%12 +17%
Net profit11 5 14 6 -6 −161%7 +25%57 +321%7 +26%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Segment breakdown

  • Specialty Chemicals
    11% Revenue Growth₹130 Cr EBITDA27% EBITDA Margin
  • Nutrition and Health Solutions
    -4% Revenue Growth
  • Chemical Intermediates
    1.5% Revenue Growth170 bps EBITDA Margin Improvement

Guidance & targets

Capex

  • Annual Capex Investment Capex · FY26 · High confidence ₹600 crore
    In FY’26, we planned to invest Rs. 600 crore in CAPEX.

    — Varun Gupta, CFO

Profitability

  • Lean 2.0 Annualized Savings Profitability · FY26 · High confidence ₹100+ crore
    As part of our Lean 2.0 cost optimization program, we have set a target of achieving annualized savings exceeding Rs 100+ crore in FY’26.

    — Deepak Jain, CEO & Managing Director

Revenue

  • Big Agro CDMO Contract Supplies Revenue · FY26 · High confidence Early 2026
    Also, CAPEX execution remains on track for the $300 million big Agro contract, and we expect to start the supplies early 2026.

    — Deepak Jain, CEO & Managing Director

  • Peak Revenue Potential Revenue · FY27 · Medium confidence ₹6,500 crore

    Previously ₹8,000 crore → ₹6,500 crore

    But the peak potential of that, I think even in the investor day, was not Rs. 8000 crore, but we had said around Rs. 6500 crore depending on the pricing.

    — Deepak Jain, CEO & Managing Director

Capacity

  • Capacity Utilization of ₹2000cr Investment Capacity · by end of FY27 · Medium confidence 70-80%
    But we do hope to utilize the capacity built through this Rs. 2000 crore to be almost 70%-80% utilized by end of FY’27.

    — Deepak Jain, CEO & Managing Director

Risks & concerns

  • Pricing volatility in Niacinamide and Acetyls

    medium

    Nutrition segment revenue declined 4% due to lower niacinamide prices; Acetyls market remains volatile despite volume recovery.

    Both acknowledged

  • Concentration in Agro CDMO customers

    medium

    Management noted there are only 4-5 big customers in the agro-segment, making contract timing critical.

    Management acknowledged

  • Global macro environment and inventory de-stocking

    low

    While de-stocking is ending, management noted that a sustained recovery pace varies by segment.

    Management acknowledged

Areas of evasion (3)

  • Specific product-level revenue for Ethyl Acetate
  • Specific therapy areas for pharma CDMO
  • Exact realization differences for Choline Chloride in Europe

Q&A highlights

2 direct
Anti-dumping duty on Choline Chloride in EU Direct
Recently, European Union has put a 125% duty on Chinese Choline Chloride, which opens up an opportunity for us... initial numbers we have gathered... run into tens of thousands of tons of market in Europe.

Reveals a significant new tailwind for the Nutrition segment that could offset domestic pricing pressure.

Asked by Siddharth Gadekar, Equirus

Clarification on peak revenue guidance Direct
We maintain that view that from today, once all of this CAPEX gets fully utilized and hopefully in FY’27, we will get closer to [Rs. 6500 crore].

Corrects analyst expectations regarding the peak revenue potential of recent investments, linking it to volatile pricing.

Asked by Pradeep Thakur, Edelweiss Mutual Fund

Asset turns and returns for CDMO business Partial
At least revenue level, we expect 1.2 to 1.3x at least and sometimes even 1.4 to 1.5x on the revenue to CAPEX ratio.

Provides specific capital efficiency metrics for the high-growth CDMO segment, though management avoided specific margin details.

Asked by Harsh Mehta, Perpetual Capital Advisors

2 min read 5 chapters

Detailed narrative

Specialty Chemicals Powers Profitability

The Specialty Chemicals segment remains the primary engine of growth, contributing 90% of the company's total EBITDA in Q1 FY26. Revenue grew 11% YoY, while EBITDA surged 52% to a record ₹130 crore, yielding a 27% margin. This performance was driven by robust demand in fine chemicals and CDMO businesses, with fine chemicals alone delivering over 15% YoY growth.

CDMO Pipeline and Agro Contract Execution

Management confirmed that the $300 million agro CDMO contract is on track for supply commencement in early 2026. The pharma CDMO funnel has doubled in size over the last few months, reflecting strong traction with innovators in the US, EU, and Japan. Additionally, the company has started deliveries for its first agro contract and is progressing on plant construction for a second one.

Strategic Pivot in Nutrition and Health

Despite a 4% YoY revenue decline in Nutrition due to lower Niacinamide pricing, the company is aggressively expanding into Human Nutrition. A dedicated team is scaling efforts in Choline Chloride and Choline Bitartrate. The imposition of a 125% anti-dumping duty on Chinese Choline Chloride in the EU is expected to significantly enhance Jubilant's competitive positioning in the European market.

Lean 2.0 and Operational Efficiency

The company is aggressively pursuing its Lean 2.0 cost-optimization program, targeting annualized savings of over ₹100 crore in FY26. These initiatives have already begun to bear fruit, particularly in the Chemical Intermediates segment, where EBITDA margins improved by 170 bps QoQ despite a volatile pricing environment. Management is also integrating Generative AI into R&D to accelerate product innovation.

Capex and Future Capacity Outlook

Jubilant Ingrevia plans to invest ₹600 crore in capex during FY26, primarily funded through internal accruals. Key projects include a new multi-purpose plant (MPP8) at Gajraula and a new boiler at Bharuch, which is 99% complete. Management expects the ₹2,000 crore total investment cycle to reach 70-80% utilization by the end of FY27, targeting a peak revenue potential of approximately ₹6,500 crore.

This is an AI-generated summary of a publicly available earnings call transcript.
View original transcript

More Healthcare earnings calls